A Randomized, Double-masked, Placebo-controlled Study to Assess the Efficacy and Safety of REGN1908-1909 to Reduce Signs and Symptoms of Allergic Conjunctivitis in Participants With Cat Allergy

This study is researching 2 experimental drugs, REGN1908 and REGN1909, which are called REGN1908-1909 when mixed together (called "study drug") to reduce eye allergy signs and symptoms from cat allergy.
The aim of the study is to see how safe and effective the study drug is at lowering allergic eye signs and symptoms compared with placebo. A placebo looks like a treatment but does not contain any real medicine.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug
* How much study drug is in the blood at different times
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

开始日期2024-11-06

申办/合作机构

Regeneron Pharmaceuticals, Inc.

NCT04981717

/ Terminated临床3期

A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients With Allergic Rhinitis Who Live With a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies During Natural Cat Exposure in the Home

The primary objective of the study is to determine the efficacy of REGN1908-1909, as compared to placebo, to reduce allergic rhinitis/conjunctivitis symptoms and allergy rescue medication use during natural cat exposure.
The Secondary Objectives are:
* To assess the reduction of allergic symptoms and use of allergy rescue medications after treatment with REGN1908-1909 versus placebo, as measured by the individual components of the CSMS
* To assess health-related quality of life (HRQoL) as measured by the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ[S])
* To determine the efficacy of REGN1908-1909, as compared to placebo, to inhibit a wheal-and-flare response to a skin prick test with cat allergen
* To assess the durability of effect in allergic rhinitis and conjunctivitis symptom and medication scores after multiple doses of REGN1908-1909 compared to placebo given every 12 weeks (Q12W)
* To determine the efficacy following multiple doses of REGN1908-1909 compared to placebo at inhibiting a wheal-and-flare response to a skin prick test with cat allergen
* To estimate the effect of REGN1908-1909 on lung function, as compared to placebo, in patients with asthma
* To determine the efficacy of REGN1908-1909 as compared to placebo to reduce asthma symptoms in patients with asthma
* To assess whether there is a difference in asthma rescue medication use in patients with asthma who are treated with REGN1908-1909 compared to placebo
* To assess whether there is a difference in nighttime awakenings in patients with asthma treated with REGN1908-1909 compared to placebo
* To evaluate the short-term and long-term safety and tolerability of REGN1908-1909, including the incidence of hypersensitivity reactions, local injection site reactions, and asthma exacerbations
* To determine systemic exposure of total (free and antigen-bound) antibodies as measured by concentration of REGN1908 and REGN1909
* To assess the immunogenicity of REGN1908 and REGN1909

开始日期2021-07-30

申办/合作机构

Regeneron Pharmaceuticals, Inc.

NCT03838731

/ Completed临床2期

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge

The primary objective is to evaluate the prophylactic efficacy of REGN1908-1909 (anti-Fel d 1) administered as a single dose on day 1 in cat-allergic asthmatic patients not living with a cat in the prevention of a Controlled Cat Allergen Challenge-induced early asthmatic response (EAR) assessed by measures of lung function (FEV1) compared to placebo-treated patients.
Secondary Efficacy Objectives:
* To evaluate the prophylactic efficacy of REGN1908-1909 administered as a single dose on day 1 in cat-allergic asthmatic patients not living with a cat, in the prevention of a Controlled Cat Allergen Challenge-induced: Allergic rhinitis and Ocular symptoms
* To evaluate the prophylactic efficacy of REGN1908-1909 administered as a single dose on day 1 in cat-allergic asthmatic patients not living with a cat to increase the exposure to cat allergen, measured as a product of minute ventilation and time, required to induce EAR in a Controlled Cat Allergen Challenge as compared to placebo patients
Secondary Safety Objective:
* To evaluate the safety and tolerability of REGN1908-1909 vs. placebo in patients with cat allergen-triggered asthma

开始日期2019-02-12

申办/合作机构

Regeneron Pharmaceuticals, Inc.

100 项与 REGN-1908-1909 相关的临床结果

登录后查看更多信息

100 项与 REGN-1908-1909 相关的转化医学

登录后查看更多信息

100 项与 REGN-1908-1909 相关的专利（医药）

登录后查看更多信息

项与 REGN-1908-1909 相关的文献（医药）

2025-09-01·Clinical and Translational Allergy

Innovative Strategies to Reduce Exposure and Expression of the Major Cat Allergen Fel d 1

Review

作者: Frattolillo, Vittoria ; Perrotta, Alessandra ; Indolfi, Cristiana ; Decimo, Fabio ; Colosimo, Simone ; Mondillo, Gianluca ; Masino, Mariapia ; Miraglia del Giudice, Michele

ABSTRACT:

Background:

Fel d 1, the primary allergen produced by cats, is a glycoprotein found mainly in their salivary and sebaceous glands. Due to its small size and stability, it easily becomes airborne and adheres to surfaces, posing a persistent problem for allergic individuals.

Methods:

This article reviews innovative strategies aimed at reducing Fel d 1 expression and exposure and mitigating its allergic effects on humans.

Results:

A key approach involves dietary supplementation with chicken egg‐derived IgY antibodies specific to Fel d 1. These antibodies neutralize the allergen in the saliva, significantly reducing its transfer to the fur and environmental presence, with clinical studies showing a notable decrease in nasal symptoms among allergic individuals. Additional dietary factors, such as omega‐3 fatty acids, polyphenols, and low‐glycemic index foods, may further modulate allergen production via hormonal and sebaceous pathways. Immunotherapy options include the Fel‐CuMV vaccine for cats and human‐targeted treatments with monoclonal antibodies like REGN1908‐1909, both of which demonstrate significant reductions in allergic symptoms. Genetic modification and hormonal manipulation (e.g., neutering) offer further avenues to lower Fel d 1 expression. Environmental strategies, including HEPA filters and protease treatments, can also help reduce allergen load in households.

Conclusions:

Together, these approaches form a multifaceted framework for managing cat allergies, potentially allowing allergic individuals to coexist with their pets. Future research should aim to optimize these interventions and explore synergistic combinations to achieve more effective and personalized allergy management.

Key Message:

This review summarizes innovative methods for reducing Fel d 1 production in cats, including genetic, immunological and dietary approaches, with potential implications for allergy prevention in humans.

项与 REGN-1908-1909 相关的新闻（医药）

2025-12-15

·同写意

再生元，收拾旧山河

100+全球先锋领袖现场开讲、50+顶尖新基建机构抢先入驻、1000+产业精英面对面链接，中国ADC和核药产业界规格最高、影响力最大、汇聚创新力量最全的年度品牌盛会！ 2025年制药巨头圈里，或许没有比再生元更扣人心弦的“反转剧本”了。这家素以研发效率著称的公司，近一年几乎尝遍行业所有苦果：核心产品销售额萎缩、关键临床数据爆冷、第三方生产“黑天鹅”事件、监管审批受阻…… 6月，当其股价跌至每股483美元、创下四年来新低时，市场已开始讨论“再生元时代”是否终结。然而过去近六个月，再生元股价已悄然回升至每股787美元——不仅收复全部失地，还比年初的每股715美元上涨10%。市场情绪基本面从怀疑转为乐观，分析师甚至给出每股850美元的目标价。这六个月究竟发生了什么？更重要的是，2026年之后，再生元还能否有更多这样的六个月？ TONACEA 01 危机四伏对于再生元而言，2025年是以一连串坏消息开局的。 2月公布的2024年第四季度财报显示，其长期以来的“现金牛”产品Eylea，销售额下降了11%，仅录得11.9亿美元。很明显，这是Eylea面对日益激烈的市场竞争时的明显疲软信号。比仿制药更快到来的，是罗氏的Vabysmo和诺华的Beovu等新一代药物。它们凭借更长的给药间隔，正在快速蚕食“老大哥”Eylea的市场。真正的重击发生在5月。彼时，被寄予厚望的IL-33单抗Itepekimab，公布了两项关键III期临床试验结果，AERIFY-1与AERIFY-2。其中一项试验取得积极成果，但另一项却未能达到预期。成功不绝对，绝对不成功——这大概是市场的心声。考虑到Itepekimab是作为明星药物Dupixent的后续产品，临床消息披露后，再生元股价重挫近19%，合作方赛诺菲股价也跌超5%。一度看好Itepekimab的Truist Securities分析师，不得不坦言“看走眼”。如果临床试验的挫折是新浮起的“瓢”，那么之前的“葫芦”仍旧没被按下去。Eylea的颓势并未止住。2025年第一季度，再生元录得该产品销售额为10.5亿美元，同比下降26%。雪上加霜的是，再生元管理层发现，他们的麻烦除了科学实验、市场挑战，还有生产环节。 8月，再生元透露，再次收到FDA针对CD20/CD3双抗Odronextamab发出的CRL。区别于第一次的数据问题，第二次CRL关键在于第三方生产现场。FDA称，负责Odronextamab罐装设施的Catalent Indiana未能通过检查。要知道，2023年，再生元就因Catalent的灌装流程缺陷，让Eylea HD（高剂量版本）上市进程被拖延。也许再生元也悔不当初——到了2025年，Odronextamab之外，三项针对不同剂量和形型的Eylea监管申请再度受影响。10月，其中一项申请甚至被正式拒绝。 BMO分析师评价说，Catalent的工厂有很多问题需要解决，依赖这些工厂生产的申请将会面临更加艰难的推进之路。就此开罪再生元有些苛刻，毕竟第三方的问题无法控制，可惜二级市场有时就是不讲道理。 6月，再生元股价创下自2021年初以来的最低水平，并在数月内都爬升艰难。 TONACEA 02 转折时刻山重水复，柳暗花明。正当外界对再生元前景担忧加剧时，转折迹象悄然出现。 2025年第二季度财报中，再生元出人意料地交了份不错的答卷，为持续低迷的情绪带来一线希望：营收36.8亿美元，超出市场预期11%；每股收益为12.89美元，比分析师预期高出53%。 Eylea系列产品遭受的威胁似乎没有想象中的大。具体而言，尽管Eylea在美国的销售额同比下降39%，但7.54亿美元的数值仍比外界预期高出6%。同时，Eylea HD营收同比增长29%至3.93亿美元，相较市场判断高出20%。 Leerink分析师统计，第二季度，再生元旗下所有Eylea产品的总销售额下降了25%，不过表现仍然比预期的要好9%，达到11.5亿美元。拳头产品Dupixent同样表现不俗。再生元报告期内，这款自免药物单季度营收飙升22%，达到43.4亿美元，超出市场预期8%，继续为其撑起创收大旗。此外，再生元旗下其他产品组合也实现了强劲增长。例如皮肤癌药物Libtayo，同比增长27%，营收3.76亿美元；用于降低胆固醇的Praluent销售额则增长16%，至2.22亿美元；而治疗炎症性疾病的Kevzara全球营收飙升39%，达到1.52亿美元。 “虽然面临监管批准的挑战，Dupixent始终是再生元的不变常数，其增长持续超出预期。”BMO分析师评价说。更何况，监管的门槛终究是跨过了几道。 8月，Odronextamab在欧盟成功破局，获批用于治疗至少接受过两种系统治疗的复发性或难治性弥漫性大B细胞淋巴瘤和滤泡性淋巴瘤。GlobalData曾估算，该药将在2029年创造4.68亿美元的全球销售额——当然，这离不开美国市场的贡献。而在11月，期待已久的Eylea HD监管许可终于到来。根据FDA同一天的公告，Eylea HD获得两项批准：一项是用于治疗视网膜静脉阻塞引起的黄斑水肿，另一项批准则为所有当前眼部注射适应症提供了每月给药一次的选项。 Leerink Partners分析师形容，这些批准使再生元“处于更好的立足点”。市场反应迅速且积极，再生元股价在几天内从每股702美元跃升至每股787美元。而鉴于Dupixent的稳定涨势，现阶段，BMO分析师预计，再生元的股价上涨有望来到每股850美元的水平。 TONACEA 03 手牌几何？随着2025年接近尾声，分析师们开始重新评估再生元的前景，发现其手中可打的牌比六个月前预想的要多。除现有产品的拓展，再生元的未来，可能受益于监管环境的变化。 12月初，Truist Securities认为，FDA的最新动向有助于减轻Itepekimab针对呼吸系统适应症的开发压力。按照STAT的报道，FDA局长Marty Makary透露，FDA计划只要求进行一项关键性临床试验——而非像以往标准那样进行两项——就会考虑批准新药。业内人士评价，这项举措无疑影响巨大。通过降低审批所需数据的门槛，制药公司可以节省数年和数十亿美元的开发成本。如果一切顺利，Makary给出的改革落地节点，是在未来三到六个月内最终敲定。这番变化下，Itepekimab的前景似乎也得重新评估。BMO分析师回顾说，半年前市场对该药物试验结果可能是过度反应，导致股价跌至不合理的水平。Itepekimab的潜力仍然存在，获批仍有机会。 BMO提醒，再生元的其他在研管线也值得关注，包括抗肌肉生长抑制素的肥胖药物Revogrumab、重症肌无力疗法Cemdisiran，以及早期过敏项目REGN5713-5715和REGN1908-1909，都可能受益于FDA新的试验指导原则。再生元对代谢疾病领域的布局，也是影响其业绩与股价走向的一大看点。 6月，以8000万美元首付款、最高19.3亿美元里程碑付款作为对价，再生元从翰森制药引进GLP-1/GIP双受体激动剂HS-20094，瞄准减重增肌的差异化市场。紧随其后，再生元公布了其“三联方案”：将肌肉生长抑制素抗体Trevogrumab和GLP-1受体激动剂Semaglutide联合，并加入激活素A抗体Garetosmab。据悉，这项名为COURAGE研究已处于II期临床阶段。援引9月举行的第61届欧洲糖尿病研究学会年会上展示的数据，“三联方案”在减脂增肌方面优势显著，可防止约50%由Semaglutide引起的肌肉损失。理论上，HS-20094的双靶点机制能做到更多的减重幅度，结合再生元的增肌药物，即使是减肥市场的后发者未尝没有赢面。 TONACEA 04 未解困局再生元在2025年下半年展现出令人印象深刻的复苏，不过挑战依然存在，有些甚至是结构性的。最紧迫的问题仍然围绕Eylea展开。例如，BMO分析师强调，再生元仍需获得Eylea预填充注射器的第三次批准才能“真正扭转局面”。面对像Beovu、Vabysmo等迅速崛起的新竞争对手，Eylea的处境远算不上能一骑绝尘。而2026年即使获得新的批准，Eylea面临的专利悬崖威胁并没有消失。 2025年，美国上诉法院驳回了再生元阻止销售Eylea生物仿制药的请求，允许安进等竞争对手进入市场。这种压力不会消失，只会随着时间推移而加剧。 Catalent带来的阴影，尚未完全散去。虽然再生元表示，它在寻找替代制造商方面取得进展，但第三方生产依赖带来的脆弱性已暴露无遗。制药行业全球化生产的今天，这种供应链风险，是几乎所有MNC都必须面对、事关产品获批的难题。2023年，FDA共发出36份CRL， 18项与生产缺陷有关。今年7月，FDA首次公开CRL数据库，2020至2024年间发出的202份CRL，CMC问题占比约一半。再生元还有更深层次的隐忧：它是否正在从对Eylea的过度依赖，转向对Dupixent的过度依赖？有目共睹，2024年成为“自免药王”的Dupixent，还在书写自己的传奇，然而殷鉴不远——上一任“自免药王”Humira之于艾伯维，基石般的肿瘤免疫疗法Keytruda之于默沙东，阵痛不可谓不大。如今的生物制药，似乎成了一场寻找“重磅炸弹”的游戏。一款超级单品注定独木难支，玩家必须持续不断地寻找新的接棒者。再生元亦不例外。另一个需要追问的挑战是，再生元在基因编辑和基因治疗领域的早期投资，何时能够转化为商业化产品？ 10月，在遗传性听力损失基因疗法方面，传来再生元的好消息：I/II期研究CHORD显示，12名患者中有11名听力得到“具有临床意义”的改善，这种变化在给药后“数周内”即可显现。尽管如此，外界认为再生元技术平台的全部潜力尚未被释放，而I/II期临床最早要在2028年10月才完成。再生元最近宣布，与Tessera Therapeutics达成合作，共同开发针对α-1抗胰蛋白酶缺乏症的基因编辑药物，交易总额高达2.75亿美元。这类布局，也依赖时间和持续的投资才能成熟。对于再生元，2025年的跌宕起伏远非终局。回想2024年8月，彼时，再生元股价创下历史新高，市值超过1300亿美元。而眼下，这根一度被Biotech看齐的“标杆”，市值相较于峰值也还是近乎腰斩。真正的考验，或许才刚刚开始。参考资料： Regeneron Climbs Back After a Year of Regulatory, Manufacturing Misery Regulatory Roadblocks Blemish Regeneron’s Otherwise Strong Q2 FDA to lower number of trials required for approval of drugs, other medical products ASH 2023: Regeneron’s odronextamab is poised to get a slice of R/R DLBCL market Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD FDA又出手，Catalent 两次坑惨再生元，新东家Novo正在善后迈入减肥药2.0时代：从减重到增肌，催化剂来了？

临床3期财报抗体药物偶联物临床结果

2025-09-09

·BioSpace

Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’

iStock, Mintr Regeneron’s antibody duos significantly lowered eye itching and redness, as well as pin prick reactivity, in people with cat and birch allergies. Still, BMO Capital Markets expressed uncertainty about the assets’ “commercial potential in a highly generic market.” Regeneron’s investigational allergen-blocking antibodies have successfully eased symptoms in two separate late-stage studies of cat and birch pollen allergies. Writing to investors on Monday, analysts at BMO Capital Markets said Regeneron’s “antibody cocktails” resulted in “robust reductions” in various allergy symptoms, including eye itchiness and redness. BMO is “broadly impressed by the strength” of Regeneron’s findings, though the firm remains uncertain about the assets’ “commercial potential in a highly generic market.” In the cat study, Regeneron tested a combination of two antibodies—REGN1908 and REGN1909—designed to target the most dominant cat allergen, a molecule called FeID1. Results showed that ocular itch was cut by 52% versus placebo, assessed one week after treatment. REGN1908 and REGN1909 likewise significantly eased conjunctival redness and skin prick reactivity, with respective effect sizes of 39% and 44%. The antibody combo had stronger efficacy in study participants whose allergies were first confirmed to have been driven by FeID1, resulting in a 65% drop in ocular itching. Similarly, Regeneron tested two other antibodies, REGN5713 and REGN5715, designed to target BetV1, the dominant allergenic birch pollen protein. Results likewise demonstrated “impressive” symptom reduction, according to BMO, with a 51% decrease in eye itching. Conjunctival redness and skin prick reactivity dropped by 46% and 44%, respectively. In both studies, Regeneron’s antibody cocktails were safe and well-tolerated, with no dropouts linked to serious treatment-related adverse events. The pharma expects to launch additional late-stage trials later this year for birch allergy and in the first half of 2026 for cat allergy. Despite these two late-stage wins, BMO raised questions regarding the market prospects of Regeneron’s antibodies. “Commercialization story remains uncertain,” the analysts wrote. “While we do not discount the number of sufferers of allergies, we need to hear more about a potential commercial strategy for Regeneron to penetrate this market, which is heavily dominated by generics like antihistamines.” Elsewhere in the allergy space, ARS Pharmaceuticals in March won the FDA’s go-ahead for the nasal-spray version of its epinephrine drug neffy, indicated for type I allergic reactions, including anaphylaxis, in children. The approval opened up the use of neffy 1-mg to kids 4 years and older who weigh from 15 kg to less than 30 kg.

临床结果上市批准

2025-09-08

·FierceBiotech

Regeneron\'s allergen-blocking antibodies score phase 3 wins against cat, pollen allergies

Both treatments were generally well tolerated, according to Regeneron.\n Regeneron’s allergen-blocking antibodies have reduced the symptoms of cat and pollen allergies in a pair of phase 3 studies.One of these studies saw 64 patients with cat allergy receive either placebo or a combination of two FelD1-blocking antibodies, dubbed REGN1908 and REGN1909. FelD1 is the most dominant cat allergen, according to Regeneron.The trial hit its primary endpoint of reducing itchy eyes with a “high degree of statistical significance” one week after treatment, the pharma said. Specifically, itchiness was reduced by 52%, while conjunctival redness and skin prick reactivity— the two secondary endpoints—were reduced by 39% and 44%, respectively.The other trial enrolled 54 patients with an allergy to birch pollen, a trigger for hay fever, who received a separate antibody combination or placebo. The treatment consisted of REGN5713 and REGN5715, monoclonal antibodies that both block BetV1, the dominant allergenic protein for birch pollen.Itchy eye was reduced by 51%, hitting the trial’s primary endpoint. Conjunctival redness and skin prick reactivity were also reduced by 46% and 44%, respectively, compared to placebo.The trials involved patients receiving the allergen—in the form of cat dander or birch pollen—directly in their eye eight days after receiving a single subcutaneous dose of the relevant allergen-blocking antibodies.Both treatments were generally well tolerated, according to Regeneron, with no serious treatment-related adverse events reported.Following the results, Regeneron said further phase 3 development for the birch pollen treatment is planned for later this year, with the cat allergy program to be pushed forward in the first half of 2026. The treatments were produced by the same VelocImmune antibody technology that Regeneron used to create its Sanofi-partnered autoimmune blockbuster Dupixent and the skin cancer drug Libtayo.Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., put this morning’s results in the context of “burdensome” allergy desensitization shots that patients can take “several times a week for several years … often with disappointing results.”“We wondered whether we could instead manufacture and directly provide allergen-blocking antibodies,” Yancopoulos, who is billed as a “co-inventor of this new approach to allergy,” said in the release.“These recent phase 3 allergen challenge trials, together with our earlier phase 2 trials, provide compelling evidence that our first-in-class approach can have the potential to provide profound allergy relief—rapidly and durably after a single treatment—decreasing ocular, nasal and even asthma measures,” Yancopoulos added.

$Regeneron\'s allergen-blocking antibodies score phase 3 wins against cat, pollen allergies$

临床结果临床3期临床2期

100 项与 REGN-1908-1909 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
变应性结膜炎	临床3期	美国	Regeneron Pharmaceuticals, Inc.	2024-11-06
变应性结膜炎	临床3期	加拿大	Regeneron Pharmaceuticals, Inc.	2024-11-06
猫过敏（疾病）	临床3期	美国	Regeneron Pharmaceuticals, Inc.	2021-07-30
猫过敏（疾病）	临床3期	比利时	Regeneron Pharmaceuticals, Inc.	2021-07-30
猫过敏（疾病）	临床3期	加拿大	Regeneron Pharmaceuticals, Inc.	2021-07-30
猫过敏（疾病）	临床3期	法国	Regeneron Pharmaceuticals, Inc.	2021-07-30
猫过敏（疾病）	临床3期	德国	Regeneron Pharmaceuticals, Inc.	2021-07-30
猫过敏（疾病）	临床3期	波兰	Regeneron Pharmaceuticals, Inc.	2021-07-30
过敏性鼻炎	临床3期	美国	Regeneron Pharmaceuticals, Inc.	2021-07-30
过敏性鼻炎	临床3期	比利时	Regeneron Pharmaceuticals, Inc.	2021-07-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04981717 (CTgov)	临床3期	过敏性鼻炎 \| 猫过敏（疾病）	446	REGN1908-1909 (REGN1908-1909)	蓋選齋願築顧構鏇鏇鹽(齋獵壓蓋獵衊簾糧膚膚) = 衊鬱艱構顧醖齋鑰構膚廠鬱醖衊醖鑰窪遞鑰鑰 (願積網憲鹹觸製鹽鏇膚, 0.9370) 更多	-	2024-06-11
				Matching Placebo (Placebo)	蓋選齋願築顧構鏇鏇鹽(齋獵壓蓋獵衊簾糧膚膚) = 鹹觸網構鏇鹽製鬱醖齋廠鬱醖衊醖鑰窪遞鑰鑰 (願積網憲鹹觸製鹽鏇膚, 0.9173) 更多
NCT03838731 (CTgov)	临床2期	猫过敏（疾病） \| 轻度哮喘	56	Placebo	鏇積艱淵糧網淵顧選淵(鹽獵鏇鑰壓築願蓋蓋製) = 膚蓋餘蓋簾選鑰齋觸膚淵齋憲觸艱鏇淵築襯淵 (膚製窪鑰鑰積蓋鬱蓋願, 齋觸獵積膚鏇遞艱繭糧 ~ 鑰壓膚顧鬱鬱鑰積艱醖) 更多	-	2021-07-01
NCT03838731 (Corporate Publications) 人工标引	临床2期	哮喘	56	REGN-1908-1909	蓋網齋憲築構網遞蓋觸(鹹簾壓獵簾獵範繭選獵) = 糧範廠廠鹹窪醖淵積顧壓醖壓簾製壓夢膚艱窪 (艱鹹艱糧壓廠積糧鬱獵 ) 更多	积极	2021-02-27
				Placebo	蓋網齋憲築構網遞蓋觸(鹹簾壓獵簾獵範繭選獵) = 顧壓願齋憲願窪餘網壓壓醖壓簾製壓夢膚艱窪 (艱鹹艱糧壓廠積糧鬱獵 ) 更多